Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Caen – page 4

659 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Caen at a glance
659
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

659 trials in Caen

Open in trial search

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Endometrial cancer

Recruiting

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Acrivon Therapeutics Inc.

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Fondation Hopital Saint Joseph

Acute myocardial infarction

Recruiting

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

Plasma cell myeloma

Recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Arthritis infective

Recruiting

A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Recruiting

Study comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Arrivent Biopharma Inc.

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

  • Advanced solid tumors
  • Hematological malignancies
  • Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

  • Viral infections
  • Bacterial infections
  • Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

  • Heart failure
  • Coronary interventions
  • Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.